Grifols (GRFS) Goodwill & Intangibles (2009 - 2025)
Grifols' (GRFS) quarterly Goodwill & Intangibles came in at $11.1 billion in Q4 2025, up 0.83% YoY from $11.0 billion in Q4 2024, and up 0.83% on a QoQ basis from $11.0 billion in Q4 2024.
Grifols (GRFS) Goodwill & Intangibles (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Goodwill & Intangibles data on file, last reported at $11.1 billion in Q4 2025.
- Quarterly Goodwill & Intangibles rose 0.83% year-over-year to $11.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.1 billion (up 0.83% YoY) and the FY2025 annual result came in at $11.1 billion, up 0.83% from the prior year.
- Goodwill & Intangibles improved to $11.1 billion in Q4 2025, from $11.0 billion in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $11.1 billion in Q4 2025 to a low of $8.8 billion in Q4 2023.
- A 5-year average of $10.0 billion and a median of $10.2 billion in 2022 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2023 — Goodwill & Intangibles fell 13.28% — and 2024, when it gained 25.24%.
- Tracing GRFS's Goodwill & Intangibles over 5 years: stood at $9.0 billion in 2021, then grew by 12.94% to $10.2 billion in 2022, then slipped by 13.28% to $8.8 billion in 2023, then grew by 25.24% to $11.0 billion in 2024, then rose by 0.83% to $11.1 billion in 2025.
- The last three Goodwill & Intangibles figures came in at $11.1 billion (Q4 2025), $11.0 billion (Q4 2024), and $8.8 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.13 Bn |
| Dec 31, 2024 | 11.04 Bn |
| Dec 31, 2023 | 8.81 Bn |
| Dec 31, 2022 | 10.16 Bn |
| Dec 31, 2021 | 9.00 Bn |
| Dec 31, 2020 | 8.21 Bn |
| Sep 30, 2020 | 8.95 Bn |
| Mar 31, 2020 | 8.61 Bn |
| Dec 31, 2019 | 8.46 Bn |
| Sep 30, 2019 | 8.77 Bn |
| Mar 31, 2019 | 8.43 Bn |
| Dec 31, 2018 | 7.53 Bn |
| Sep 30, 2018 | 7.65 Bn |
| Jun 30, 2018 | 7.56 Bn |
| Mar 31, 2018 | 7.11 Bn |
| Dec 31, 2017 | 6.90 Bn |
| Jun 30, 2017 | 6.74 Bn |
| Dec 31, 2016 | 5.23 Bn |
| Sep 30, 2016 | 5.11 Bn |
| Jun 30, 2016 | 5.20 Bn |